Battlefield Pain Management – Analgesic

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT942726RE009

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AN13

Additional Details
Set Aside

NONE

Place of Performance

Frederick, Maryland, UNITED STATES

SourceSAM
The Defense Health Agency (DHA), through its Contracting Activity (DHACA) and the Portfolio Acquisition Executive Medical Products (PAE MP) Warfighter Protection and Acute Care Project Management Office (WPAC PMO) at Fort Detrick in Frederick, Maryland, has issued a Request for Prototype Proposal (RPP) under the authority of 10 U.S.C. 4022, known as the prototype Other Transaction Authority (pOTA). This solicitation seeks innovative solutions for the development of an analgesic product specifically designed for battlefield use, with the overarching goal of enhancing pain management capabilities for warfighters in operational environments. The scope of this procurement centers on research and development activities in biotechnology, as indicated by the NAICS code 541714 (Research and Development in Biotechnology, except Nanobiotechnology). The intended outcome is the prototyping of an analgesic product that meets the unique requirements of battlefield application, supporting the acute care needs of military personnel. The government is seeking proposals that address both the technical and operational challenges associated with delivering effective pain management in austere and dynamic combat settings. Key requirements and objectives are detailed in the attached RPP and its amendments, including a Statement of Objectives (SOO) that outlines the desired characteristics and performance metrics for the prototype. Notably, Amendment 0001 to the RPP has clarified the language throughout the solicitation, ensuring consistency in referring to the requirement as a "product" rather than a "drug." The amendment also extends the proposal due date to August 14, 2026, and provides additional guidance on administrative and cost volume submissions, including updates to the Spend Plan and the addition of new vendor requirements. The deliverables for this effort have been revised in the latest amendment, with specific changes to Deliverable 3 and Deliverable 12, as well as updates to several desirable prototype characteristics and performance criteria. These modifications reflect the government's intent to ensure that the proposed solutions are aligned with operational needs and technical feasibility. The RPP also includes responses to questions from potential offerors, providing further clarification on the government's expectations. This opportunity is not subject to any set-aside restrictions, making it open to all qualified entities capable of meeting the requirements. The place of performance is Frederick, Maryland, and the contracting entity is the Defense Health Agency, a federal office under the Department of Defense. The primary and secondary points of contact for this solicitation are Shannon Lertora ([email protected]) and Peter Mitchell ([email protected]), respectively. Interested parties are encouraged to review the full RPP and its attachments, available via the SAM.gov opportunity ID 31e3dea0a4874442b2ad847abac50974, to ensure a comprehensive understanding of the technical, administrative, and performance requirements. The solicitation remains active, and proposals must be submitted by August 14, 2026. This procurement represents a significant opportunity for organizations specializing in biotechnology research and development, particularly those with expertise in medical product prototyping for military or austere environments. Contractors should assess their capabilities against the stated objectives and deliverables to determine alignment with the government's needs and the potential for successful participation in this initiative.
Documents12